CMLTU News and Press, CM Life Sciences III Inc. Unit

Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceeds Combined company to trade on Nasdaq Global Market under ticker “EQRX” NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (Nasdaq...

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III Inc. (Nasdaq: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of...

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that management will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Conference. The firesid...

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a strategic collaboration agreement with Abdul Latif Jameel Health , part of international diversified family business A...

EQRx to leverage Evotec’s unique data-driven integrated drug discovery and development accelerator platform; partnership aims to build up jointly owned pipeline to deliver innovative, affordable and accessible medicines to patients EQRx, a new type of pharmaceutical c...

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today launched a multi-part corporate video series entitled “Remaking Medicine: On The Record.” The series is moderated by Jami ...

Absci’s AI-powered discovery and development platform to further expand EQRx’s portfolio of innovative, affordable medicines EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower...

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the appointment of Kathy Giusti to the Company’s board of directors. Ms. Giusti is recognized as a pioneer in precision...

- Sugemalimab is the first PD-(L)1 monoclonal antibody to demonstrate a progression-free survival benefit in Stage III NSCLC patients after treatment with either concurrent or sequential chemoradiotherapy in a pivotal Phase 3 study - Results from Stage III and Stage IV studies...

- Updated data presented at IASLC 2021 World Conference on Lung Cancer includes final PFS analysis and preliminary OS results in Stage IV NSCLC EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically ...